Abstract
The clinical trial networks that included a maternal-child focus have evolved since first funded by NIH in the 1990s. Since then, US domestic and international sites were combined into one network, with a focused agenda on therapeutics (for both prevention and treatment), human immunodeficiency virus (HIV) cure, tuberculosis, and complications of HIV, largely specific to the brain. Key to the success of the network has been a strong partnership with the community, collaborations with industry and other strategic partners, and recognition that one size does not fit all when it comes to antiretrovirals, diagnosing and treating TB, and other treatments for our populations.